Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator

Ying Xian, Li Liang, Eric E. Smith, Lee H. Schwamm, Mathew J. Reeves, DaiWai M. Olson, Adrian F. Hernandez, Gregg C. Fonarow, Eric D. Peterson

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Context: Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an increased risk for intracranial hemorrhage when treated with tPA. Although current guidelines endorse administering intravenous tPA to warfarin-treated patients if their international normalized ratio (INR) is 1.7 or lower, there are few data on safety of intravenous tPA in warfarin-treated patients in clinical practice. Objectives: To determine the risk of symptomatic intracranial hemorrhage (sICH) among patients with ischemic stroke treated with intravenous tPA who were receiving warfarin vs those who were not and to determine this risk as a function of INR. Design, Setting, and Patients: Observational study, using data from the American Heart Association Get With The Guidelines-Stroke Registry, of 23 437 patients with ischemic stroke and with INR of 1.7 or lower, treated with intravenous tPA in 1203 registry hospitals from April 2009 through June 2011. Main Outcome Measure: Symptomatic intracranial hemorrhage. Secondary end points include life-threatening/serious systemic hemorrhage, any tPA complications, and in-hospital mortality. Results: Overall, 1802 (7.7%) patients with stroke treated with tPA were receiving warfarin (median INR, 1.20; interquartile range [IQR], 1.07-1.40). Warfarin-treated patients were older, had more comorbid conditions, and had more severe strokes. The unadjusted sICH rate in warfarin-treated patients was higher than in non-warfarintreated patients (5.7% vs 4.6%, P<.001), but these differences were not significantly different after adjustment for baseline clinical factors (adjusted odds ratio [OR], 1.01 [95% CI, 0.82-1.25]). Similarly, there were no significant differences between warfarin-treated and non-warfarin-treated patients for serious systemic hemorrhage (0.9% vs 0.9%; adjusted OR, 0.78 [95% CI, 0.49-1.24]), any tPA complications (10.6% vs 8.4%; adjusted OR, 1.09 [95% CI, 0.93-1.29]), or in-hospital mortality (11.4% vs 7.9%; adjusted OR, 0.94 [95% CI, 0.79-1.13]). Among warfarin-treated patients with INRs of 1.7 or lower, the degree of anticoagulation was not statistically significantly associated with sICH risk (adjusted OR, 1.10 per 0.1-unit increase in INR [95% CI, 1.00-1.20]; P=.06). Conclusion: Among patients with ischemic stroke, the use of intravenous tPA among warfarin-treated patients (INR≤1.7) was not associated with increased sICH risk compared with non-warfarin-treated patients.

Original languageEnglish (US)
Pages (from-to)2600-2608
Number of pages9
JournalJAMA - Journal of the American Medical Association
Volume307
Issue number24
DOIs
StatePublished - Jun 20 2012

Fingerprint

Intracranial Hemorrhages
Tissue Plasminogen Activator
Warfarin
Stroke
International Normalized Ratio
Odds Ratio
Hospital Mortality
Registries
Guidelines
Hemorrhage
Observational Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. / Xian, Ying; Liang, Li; Smith, Eric E.; Schwamm, Lee H.; Reeves, Mathew J.; Olson, DaiWai M.; Hernandez, Adrian F.; Fonarow, Gregg C.; Peterson, Eric D.

In: JAMA - Journal of the American Medical Association, Vol. 307, No. 24, 20.06.2012, p. 2600-2608.

Research output: Contribution to journalArticle

Xian, Ying ; Liang, Li ; Smith, Eric E. ; Schwamm, Lee H. ; Reeves, Mathew J. ; Olson, DaiWai M. ; Hernandez, Adrian F. ; Fonarow, Gregg C. ; Peterson, Eric D. / Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. In: JAMA - Journal of the American Medical Association. 2012 ; Vol. 307, No. 24. pp. 2600-2608.
@article{c640436ed24d4a04b405a192af081b6c,
title = "Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator",
abstract = "Context: Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an increased risk for intracranial hemorrhage when treated with tPA. Although current guidelines endorse administering intravenous tPA to warfarin-treated patients if their international normalized ratio (INR) is 1.7 or lower, there are few data on safety of intravenous tPA in warfarin-treated patients in clinical practice. Objectives: To determine the risk of symptomatic intracranial hemorrhage (sICH) among patients with ischemic stroke treated with intravenous tPA who were receiving warfarin vs those who were not and to determine this risk as a function of INR. Design, Setting, and Patients: Observational study, using data from the American Heart Association Get With The Guidelines-Stroke Registry, of 23 437 patients with ischemic stroke and with INR of 1.7 or lower, treated with intravenous tPA in 1203 registry hospitals from April 2009 through June 2011. Main Outcome Measure: Symptomatic intracranial hemorrhage. Secondary end points include life-threatening/serious systemic hemorrhage, any tPA complications, and in-hospital mortality. Results: Overall, 1802 (7.7{\%}) patients with stroke treated with tPA were receiving warfarin (median INR, 1.20; interquartile range [IQR], 1.07-1.40). Warfarin-treated patients were older, had more comorbid conditions, and had more severe strokes. The unadjusted sICH rate in warfarin-treated patients was higher than in non-warfarintreated patients (5.7{\%} vs 4.6{\%}, P<.001), but these differences were not significantly different after adjustment for baseline clinical factors (adjusted odds ratio [OR], 1.01 [95{\%} CI, 0.82-1.25]). Similarly, there were no significant differences between warfarin-treated and non-warfarin-treated patients for serious systemic hemorrhage (0.9{\%} vs 0.9{\%}; adjusted OR, 0.78 [95{\%} CI, 0.49-1.24]), any tPA complications (10.6{\%} vs 8.4{\%}; adjusted OR, 1.09 [95{\%} CI, 0.93-1.29]), or in-hospital mortality (11.4{\%} vs 7.9{\%}; adjusted OR, 0.94 [95{\%} CI, 0.79-1.13]). Among warfarin-treated patients with INRs of 1.7 or lower, the degree of anticoagulation was not statistically significantly associated with sICH risk (adjusted OR, 1.10 per 0.1-unit increase in INR [95{\%} CI, 1.00-1.20]; P=.06). Conclusion: Among patients with ischemic stroke, the use of intravenous tPA among warfarin-treated patients (INR≤1.7) was not associated with increased sICH risk compared with non-warfarin-treated patients.",
author = "Ying Xian and Li Liang and Smith, {Eric E.} and Schwamm, {Lee H.} and Reeves, {Mathew J.} and Olson, {DaiWai M.} and Hernandez, {Adrian F.} and Fonarow, {Gregg C.} and Peterson, {Eric D.}",
year = "2012",
month = "6",
day = "20",
doi = "10.1001/jama.2012.6756",
language = "English (US)",
volume = "307",
pages = "2600--2608",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "24",

}

TY - JOUR

T1 - Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator

AU - Xian, Ying

AU - Liang, Li

AU - Smith, Eric E.

AU - Schwamm, Lee H.

AU - Reeves, Mathew J.

AU - Olson, DaiWai M.

AU - Hernandez, Adrian F.

AU - Fonarow, Gregg C.

AU - Peterson, Eric D.

PY - 2012/6/20

Y1 - 2012/6/20

N2 - Context: Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an increased risk for intracranial hemorrhage when treated with tPA. Although current guidelines endorse administering intravenous tPA to warfarin-treated patients if their international normalized ratio (INR) is 1.7 or lower, there are few data on safety of intravenous tPA in warfarin-treated patients in clinical practice. Objectives: To determine the risk of symptomatic intracranial hemorrhage (sICH) among patients with ischemic stroke treated with intravenous tPA who were receiving warfarin vs those who were not and to determine this risk as a function of INR. Design, Setting, and Patients: Observational study, using data from the American Heart Association Get With The Guidelines-Stroke Registry, of 23 437 patients with ischemic stroke and with INR of 1.7 or lower, treated with intravenous tPA in 1203 registry hospitals from April 2009 through June 2011. Main Outcome Measure: Symptomatic intracranial hemorrhage. Secondary end points include life-threatening/serious systemic hemorrhage, any tPA complications, and in-hospital mortality. Results: Overall, 1802 (7.7%) patients with stroke treated with tPA were receiving warfarin (median INR, 1.20; interquartile range [IQR], 1.07-1.40). Warfarin-treated patients were older, had more comorbid conditions, and had more severe strokes. The unadjusted sICH rate in warfarin-treated patients was higher than in non-warfarintreated patients (5.7% vs 4.6%, P<.001), but these differences were not significantly different after adjustment for baseline clinical factors (adjusted odds ratio [OR], 1.01 [95% CI, 0.82-1.25]). Similarly, there were no significant differences between warfarin-treated and non-warfarin-treated patients for serious systemic hemorrhage (0.9% vs 0.9%; adjusted OR, 0.78 [95% CI, 0.49-1.24]), any tPA complications (10.6% vs 8.4%; adjusted OR, 1.09 [95% CI, 0.93-1.29]), or in-hospital mortality (11.4% vs 7.9%; adjusted OR, 0.94 [95% CI, 0.79-1.13]). Among warfarin-treated patients with INRs of 1.7 or lower, the degree of anticoagulation was not statistically significantly associated with sICH risk (adjusted OR, 1.10 per 0.1-unit increase in INR [95% CI, 1.00-1.20]; P=.06). Conclusion: Among patients with ischemic stroke, the use of intravenous tPA among warfarin-treated patients (INR≤1.7) was not associated with increased sICH risk compared with non-warfarin-treated patients.

AB - Context: Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an increased risk for intracranial hemorrhage when treated with tPA. Although current guidelines endorse administering intravenous tPA to warfarin-treated patients if their international normalized ratio (INR) is 1.7 or lower, there are few data on safety of intravenous tPA in warfarin-treated patients in clinical practice. Objectives: To determine the risk of symptomatic intracranial hemorrhage (sICH) among patients with ischemic stroke treated with intravenous tPA who were receiving warfarin vs those who were not and to determine this risk as a function of INR. Design, Setting, and Patients: Observational study, using data from the American Heart Association Get With The Guidelines-Stroke Registry, of 23 437 patients with ischemic stroke and with INR of 1.7 or lower, treated with intravenous tPA in 1203 registry hospitals from April 2009 through June 2011. Main Outcome Measure: Symptomatic intracranial hemorrhage. Secondary end points include life-threatening/serious systemic hemorrhage, any tPA complications, and in-hospital mortality. Results: Overall, 1802 (7.7%) patients with stroke treated with tPA were receiving warfarin (median INR, 1.20; interquartile range [IQR], 1.07-1.40). Warfarin-treated patients were older, had more comorbid conditions, and had more severe strokes. The unadjusted sICH rate in warfarin-treated patients was higher than in non-warfarintreated patients (5.7% vs 4.6%, P<.001), but these differences were not significantly different after adjustment for baseline clinical factors (adjusted odds ratio [OR], 1.01 [95% CI, 0.82-1.25]). Similarly, there were no significant differences between warfarin-treated and non-warfarin-treated patients for serious systemic hemorrhage (0.9% vs 0.9%; adjusted OR, 0.78 [95% CI, 0.49-1.24]), any tPA complications (10.6% vs 8.4%; adjusted OR, 1.09 [95% CI, 0.93-1.29]), or in-hospital mortality (11.4% vs 7.9%; adjusted OR, 0.94 [95% CI, 0.79-1.13]). Among warfarin-treated patients with INRs of 1.7 or lower, the degree of anticoagulation was not statistically significantly associated with sICH risk (adjusted OR, 1.10 per 0.1-unit increase in INR [95% CI, 1.00-1.20]; P=.06). Conclusion: Among patients with ischemic stroke, the use of intravenous tPA among warfarin-treated patients (INR≤1.7) was not associated with increased sICH risk compared with non-warfarin-treated patients.

UR - http://www.scopus.com/inward/record.url?scp=84862858987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862858987&partnerID=8YFLogxK

U2 - 10.1001/jama.2012.6756

DO - 10.1001/jama.2012.6756

M3 - Article

C2 - 22735429

AN - SCOPUS:84862858987

VL - 307

SP - 2600

EP - 2608

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 24

ER -